Warning Letters | FDA
FDA issued two new warning letters on 06/30/2026 and 06/24/2026 to Excelvision - Fareva and Wizcure Pharmaa Private Limited for CGMP violations related to adulterated finished pharmaceuticals. While these letters target drug manufacturers, they signal increased FDA scrutiny on CGMP compliance, which may extend to dietary supplement facilities. Supplement businesses should review their own CGMP practices to avoid similar enforcement.
Aforeworn detected this change in the Dietary-Supplement Labeling (FDA) space on July 7, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Supplement brands, contract manufacturers, private-label sellers, ingredient suppliers should confirm how it applies to their specific situation before acting. There is a time constraint attached: Within 30 days to address any identified gaps before FDA inspection.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Dietary-Supplement Labeling (FDA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Two new warning letters issued for CGMP violations in finished pharmaceuticals, indicating FDA is actively enforcing CGMP requirements.
Who it affects
Supplement brands, contract manufacturers, private-label sellers, ingredient suppliers
What you must do
Review your facility's CGMP compliance, including quality control, recordkeeping, and sanitation procedures. Ensure any drug or supplement products are manufactured in accordance with current good manufacturing practices.
Deadline
Within 30 days to address any identified gaps before FDA inspection.
Never miss a change like this again
Aforeworn watches Dietary-Supplement Labeling (FDA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Dietary-Supplement Labeling (FDA)
- FTC Sends Warning Letters to Companies About Compliance with the TAKE IT DOWN Act
- FTC Sues to Stop Amare Global Holdings from Misrepresenting the Health Benefits of Its Dietary Supplements for Children and Adults
- FTC Issues Report to Congress on Adoption Practices
- FTC Files Contempt Motion Against Amare Global and Three Individuals Over Unsubstantiated Health Claims
- FTC Warns Companies Making Questionable ‘Made in the USA’ Claims